# A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors

> **NCT04857372** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 137 (actual)

## Conditions studied

- Mesothelioma

## Interventions

- **DRUG:** IAG933

## Key facts

- **NCT ID:** NCT04857372
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-21
- **Primary completion:** 2026-09-04
- **Final completion:** 2026-09-04
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2025-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04857372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04857372, "A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04857372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*